

## Applications of statistical methodology in early drug development - Advanced-draft agenda

por webadmin - Lunes, junio 01, 2015

<http://www.biometricsociety.net/2015/06/01/applications-of-statistical-methodology-in-early-drug-development-advanced-draft-agenda/>

Dear Colleague,

I am pleased to inform you that the 6th edition of the *European Statistical Forum* will be held in **Vienna on Monday, 16th November**.

The sixth edition of the *European Statistical Forum* is dedicated to the application of statistical methodology in early drug development, focusing in particular on:

- Current state-of-the art dose finding trial designs like MCPMod
- Statistical techniques on the integration of biomarker as well as pharmacogenetic data into the early drug development process
- Implementation of efficient Proof of Principle and Proof of Concept trials
- Transfer of the preclinical knowledge into first in human trials
- New developments in and designs for PK and PK/PD trials
- Recent enhancements in statistical methodology by leaders in academia

Both case studies and methodological background will be covered. The conference aims at promoting the exchange of expertise, bringing together statisticians, pharmacometricians, physicians, regulators, academia and other experts interested in the field of early drug development.

An advanced-draft agenda is now available. The Scientific Board, **Jens-Otto Andreas** (*Head EU Biostatistics at UCB Biosciences GmbH*), **Lisa Comarella** (*Director Biostatistics and Senior Project Manager at CROS NT Group*), **Frank Fleischer** (*Global BCA at Boehringer Ingelheim Pharma GmbH & Co. KG*) and **Giacomo Mordenti** (*Senior Director Compound Development & Branding-Head Biostatistics at Grünenthal*) will moderate the conference and speeches of expert Speakers, who will cover the following subjects:

### *A Statistical Framework for Decision Making in Early Clinical Development*

**James Matcham** – Head, Early Clinical Development Biometrics, AstraZeneca UK

### *Efficient design of an academic dose finding trial with intraindividual comparison to placebo*

**Arne Ring** – Professor of Statistics and Principal Statistician, University of Leicester

### *MCP-Mod in longitudinal phase II trials – practical experiences in the pharmaceutical industry*

**Lieven Kennes** – Department of Biometrics, Grünenthal GmbH

### *Incorporating a search for predictive biomarkers into clinical trials*

**Foteini Strimenopoulou** – Principal Exploratory Statistician, UCB UK

**Ros Walley** – Director Exploratory Statistics, UCB UK

*Statistics in Early Clinical Development – The Way Ahead of Us*

**Harry Mager** – Senior Director / Expert Statistician Pharmacometrics – Early Drug Development, Bayer Pharma AG, Berlin

**Richardus Vonk** – Senior Director, Head of Research and Clinical Sciences Statistics, Bayer Pharma AG

*Maximize your ability to make predictions using Bayesian optimal designs*

**Bruno Boulanger** – CSO, Arlenda

*MCPMod for the Adaptive Design and Analysis of Dose-Finding studies under Model-uncertainty*

**Tobias Mielke** – Statistical Consultant, ICON PLC

*The final agenda will be available soon*

Click [here](#) to read abstracts

**[REGISTRATION>>](#)**

**[Early Bird discount for enrolment by 16th October](#)**

***Free pre-Conference Dinner for registration forms received before June 26th.***

For further information or if you would like to reserve a place, please visit the [European Statistical Forum](#) website and do not hesitate to contact me.

Looking forward to meeting you in Vienna,

Best Regards,

Chiara Garofalo

*Project and Scientific Manager*

European Statistical Forum – EasyB S.r.l.

---

PDF generado por unlimioo para la Asociación Española de Biometría